BRIEF published on 11/20/2024 at 15:33, 21 hours 58 minutes ago Braidwell LP Crosses Thresholds at DBV Technologies Actions Investment Crossing Thresholds DBV Technologies Braidwell LP
BRIEF published on 11/06/2024 at 22:35, 14 days 14 hours ago DBV Technologies Facing Financial Uncertainties in Q3 2024 Financial Results Cash Flow Net Loss Q3 2024 DBV Technologies
PRESS RELEASE published on 11/06/2024 at 22:30, 14 days 15 hours ago DBV Technologies Reports Third Quarter 2024 Financial Results DBV Technologies reports Q3 2024 financial results, with $46.4 million cash balance. Approves quarterly financial statements. Faces challenges in securing future financing Financial Results Financing Clinical Trials Cash Balance DBV Technologies
BRIEF published on 10/31/2024 at 09:05, 21 days 4 hours ago Braidwell LP Crosses Thresholds in DBV Technologies Warrants Actions DBV Technologies Participation Threshold Braidwell LP
BRIEF published on 10/22/2024 at 22:50, 29 days 14 hours ago DBV's Viaskin Peanut Patch Secures Regulatory Progress in US and EU FDA Approval DBV Technologies Viaskin Peanut Regulatory Update EMA Guidance
PRESS RELEASE published on 10/22/2024 at 22:45, 29 days 14 hours ago DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV Technologies announces positive regulatory updates for Viaskin Peanut Patch in the United States and Europe, aiming for Accelerated Approval for toddlers 1-3 years old Accelerated Approval Regulatory Updates DBV Technologies Viaskin Peanut Patch Toddlers
BRIEF published on 10/18/2024 at 22:35, 1 month 2 days ago DBV Technologies to Engage in ACAAI 2024 Congress DBV Technologies Allergy Treatment Peanut Allergy Viaskin Peanut Patch ACAAI 2024
PRESS RELEASE published on 10/18/2024 at 22:30, 1 month 2 days ago DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies to participate in ACAAI 2024 Congress, presenting on optimal peanut allergy treatment and sponsoring FIT Bowl. Viaskin Peanut patch for food allergies highlighted DBV Technologies Food Allergies Viaskin Peanut Patch ACAAI 2024 Congress Peanut Allergy Treatment
BRIEF published on 10/14/2024 at 22:35, 1 month 6 days ago DBV Technologies Share Capital Status as of September 30, 2024 Share Capital Voting Rights DBV Technologies Euronext Exchanges Listed Shares
BRIEF published on 09/23/2024 at 22:35, 1 month 27 days ago DBV Technologies Completes Screening of Subjects for Phase 3 VITESSE Clinical Trial Clinical Trial Phase 3 DBV Technologies Viaskin Peanut Peanut Allergy
Published on 11/21/2024 at 13:00, 32 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 32 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 32 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 32 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 32 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 56 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 17 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 34 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 12 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 47 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 47 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
